Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer

Adenocarcinoma of the Prostate Clinical Trial

Official title:

A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01054079
• Other study ID #: IRB00009741
• Secondary ID: NCI-2009-01514CC
• Status: Completed
• Phase: Phase 2
• Start date: September 2011
• Est. completion date: August 2014

Study information

• Verified date: July 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with recurrent prostate cancer that has not responded to previous treatment

Description:

PRIMARY OBJECTIVES:

I. To test the hypothesis that once-daily treatment with 30 mg of cinacalcet hydrochloride (Sensipar) will reduce the rate of rise of serum prostate-specific antigen (PSA) compared to pre-treatment PSA values in subjects with biochemically recurrent prostate cancer after failed definitive local therapy.

OUTLINE:

Patients receive cinacalcet hydrochloride orally (PO) once daily (QD) for 20 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate

• For patients who have recurrent disease following surgery as first line therapy ("surgical failures")

• PSA requirement is 0.2 ng/ml or above

• For patients who have recurrent disease following radiation as first line therapy, the eligibility follows the "Phoenix criteria", that is, a rise of 2 ng/mL over the PSA nadir

• Eastern Cooperative Oncology Group (ECOG) performance status =< 2

• Granulocytes >= 1000/uL

• Serum creatinine =< 2.0 mg/dl

• Total serum calcium > 9.0 and < 10.5 mg/dl

• Total bilirubin =< 2.0 mg/dl

• Platelet count >=100,000/uL

• Hemoglobin (Hgb) >= 9 g/dL

• Total testosterone >= 50 ng/dL

• Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)

Exclusion Criteria:

• Serious medical illness which would limit survival to less than 3 months

• Active, uncontrolled bacterial, viral or fungal infection

• Hemorrhagic disorder

• Any radiographic evidence of metastatic disease including positive bone scan or computed tomography (CT) abdomen/pelvis

• History of hypocalcemia or seizure disorder

• Patients with known hypersensitivity to any of the components of cinacalcet (cinacalcet hydrochloride)

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Prostate
• Prostatic Neoplasms
• Recurrent Prostate Cancer

Intervention

Other:
• laboratory biomarker analysis
Correlative study

Procedure:
• quality-of-life assessment
Ancillary study

Other:
• questionnaire administration
Ancillary study

Drug:
• cinacalcet hydrochloride
Given PO

Locations

Country	Name	City	State
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Rise of Serum PSA	The difference of post treatment and pre-enrollment PSA.For those with multiple PSA measures post we use the median of those measures to estimate the participant's post PSA level.	24 weeks
Secondary	Change in Quality of Life (QOL) as Assessed by the Brief Male Sexual Inventory	The Brief Male Sexual Inventory is an 11 question assessment including subscales: sex drive, erections, ejaculation. The scores are totaled to produce an overall score with a range of 1-45, with higher score indicating worse outcomes.	Up to 20 weeks
Secondary	Change in Hormonal Assessment Scale From Expanded Prostate Cancer Index Composite (EPIC)	The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Epic produces two scores, one for function (5 items) and the other for bother (6 items). The response for each item is standardized to a 0 to 100 scale. For both scales, higher scores indicate worse outcomes.	up to 20 weeks
Secondary	Change in Functional Assessment of Cancer Therapy-Prostate (FACT-P)	The FACT-P is a multidimensional, self-report QoL instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain, as well as a global QoL score. All subscale items are summed to a total. The score range is 0-156. Higher scores represent better quality of life.	up to 20 weeks
Secondary	Change in Total and Free Testosterone	The detectable difference is estimated using a paired t-test approach. The lab measure will also be analyzed longitudinally using all measures with a mixed model approach adjusting for individual covariates.	Up to 20 weeks